Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-25

Study Completion Date

2026-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the between-arm difference in the proportion of subjects achieving complete closure of hard-to-heal venous leg ulcers (VLU) between Intact Fish Skin Graft plus standard of care (IFSG/SOC) versus standard of care alone (SOC) over 12 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

NCT06826339

Venous Leg Ulcer Venous Leg Diabetic Foot +6 more

RECRUITING PHASE4

Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

NCT04927702

Diabetic Foot Ulcer Venous Leg Ulcer

TERMINATED NA

Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy

NCT07086443

Diabetic Foot Ulcer DFU Diabetic Foot Ulcer (DFU) +4 more

RECRUITING PHASE4

Bioactive Split Thickness Skin Allograft Versus Standard of Care in the Treatment of Diabetic Foot Ulcers

NCT04040426

Diabetic Foot Ulcer Foot

COMPLETED NA

Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.

NCT06437028

Diabetic Foot Ulcer

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized controlled multicenter clinical trial evaluating intact fish skin grand and standard of care vs. standard of care alone in nonhealing venous leg ulcers. The product classifies as a medical device and consists of a full thickness fish-skin that has been processed using Kerecis™ Limited's proprietary EnviroIntact™ method.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Leg Ulcer (VLU) Venous Leg Ulcers Venous Leg Nonhealing Venous Leg Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multicenter Prospective Randomized Comparative Effectiveness Clinical Trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intact Fish Skin Graft (IFSG) + Standard of Care

Up to 12 visits with Intact Fish Skin Graft (IFSG) + Standard of Care.

Group Type EXPERIMENTAL

Intact Fish Skin Graft (IFSG) + Standard of Care

Intervention Type OTHER

Participants will receive weekly applications of MariGen and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Standard of Care

Standard of care will be cleaning, debridement, ulcer moisture balance, and offloading.

Group Type ACTIVE_COMPARATOR

Standard of Care

Intervention Type OTHER

Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intact Fish Skin Graft (IFSG) + Standard of Care

Participants will receive weekly applications of MariGen and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Intervention Type OTHER

Standard of Care

Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects must be at least 18 years of age or older.
2. Subjects must have a nonhealing venous leg ulcer present for a minimum of 4 weeks and cannot have received more than 52 weeks of high-level compression prior to the initial screening visit.
3. No visible signs of healing objectively, less than 40% reduction in wound size in the last 4 weeks.
4. At randomization, subjects must have a target ulcer with a minimum surface area of 1 cm2 and a maximum surface area of 25 cm2 measured post-debridement.
5. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:

1. ABI between 0.7 and ≤ 1.3;
2. TBI ≥ 0.6;
3. TCOM ≥ 40 mmHg;
4. PVR: biphasic.

Exclusion Criteria

7. Subjects must have a Functional Ambulatory Category Score (FACS) of 3 or greater.
8. Subjects must consent to using the prescribed compression method for the duration of the study.
9. Subjects must agree to attend the weekly study visits required by the protocol.
10. Subjects must be willing and able to participate in the informed consent process.

1. The potential subject is known to have a life expectancy of \< 6 months.
2. The index ulcer is determined to be due to a condition other than venous insufficiency.
3. The target ulcer exposes muscle, tendon, or bone.
4. The target ulcer exhibits overt clinical signs and symptoms of infection with cellulitis surrounding the wound margin.
5. The target ulcer has known or suspected skin malignancy.
6. The target ulcer has been previously exposed to radiation.
7. The target ulcer duration is greater than one year having received high level compression without closure for a year or more.
8. The potential subject has end stage renal disease requiring dialysis.
9. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
10. A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
11. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a cellular or tissue-based product (CTP) in the 30 days prior to the initial screening visit.
12. The potential subject has a malnutrition indicator score \<17 as measured on the Mini Nutritional Assessment.
13. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
14. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Digital planimetry is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).
15. The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.
16. The potential subject has a Functional Ambulatory Category Score (FACS) of less than 3.
17. The potential subject has a body mass index (BMI) greater than 42
18. In the last 8 weeks the patient has undergone revascularization (surgical or stenting) to the affected leg.
19. Venous intervention in the affected limb in the last 30 days.
20. Presence of any condition (including current drug or alcohol abuse, medical or psychiatric condition) that is likely to impair understanding of or compliance with the study protocol in the judgment of the Investigator.
21. Pregnancy at enrollment or women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study OR are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
22. Know allergy to any of the components of fish skin or bovine collagen.
23. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.
24. A subject with a disorder that would create unacceptable risk of post-operative complications is excluded.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No